JW Jungwoo Pharmaceutical and Deargen Sign Joint Research Agreement for AI-Based Drug Development

Shin Young-seop, CEO of JW Jungwoo Pharmaceutical (left), and Kang Gil-soo, CEO of Deargen, are posing for a commemorative photo.

[Asia Economy Reporter Lee Gwan-ju] JW Pharmaceutical announced on the 6th that it has signed a joint research agreement with AI new drug development specialist Deargen to develop innovative new drugs based on artificial intelligence (AI).

Under this agreement, the two companies will use Deargen's AI new drug development platform 'DEARGEN iDears' to explore new indications for the new drug candidates being developed by JW Pharmaceutical and verify their development potential.

Deargen's platform not only optimizes the search for indications for existing drugs but also shortens the early research stages of new drug development, including new drug discovery and design, and in-vitro efficacy verification. The UK pharmaceutical bio-investment research firm 'Deep Pharma Intelligence' selected it as the global top AI new drug development platform company for three consecutive years in a report published in the first quarter of this year.

Deargen CEO Kang Gil-su said, “We are pleased to conduct joint research with JW Pharmaceutical, which has the technology and know-how in new drug research and development,” adding, “Through this collaboration, we will actively cooperate to ensure that Deargen's new drug development platform contributes to securing JW Pharmaceutical's new drug pipeline.”

JW Pharmaceutical CEO Shin Young-seop emphasized, “We expect to secure a new innovative drug pipeline through joint research utilizing Deargen's global-level AI platform,” and added, “We will continue to pursue differentiated open innovation that creates synergy not only in new drug research based on the JW platform but also with new technologies.”

JW Pharmaceutical is promoting an open innovation strategy to expand new modalities (therapeutic approaches) for its self-developed new drug candidates. This year alone, it has signed joint research agreements with four domestic biotech companies, including Deargen, Ilias Biologics, Organoid Science, and Oncocross. In July, it also became the first domestic pharmaceutical company to collaborate with Arch Venture Partners, the largest venture capital (VC) firm in the United States.

This content was produced with the assistance of AI translation services.